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• Tobacco harm reduction aims to reduce illness and death caused by smoking tobacco.
• The medical and regulatory consensus is that nicotine itself is relatively safe.
• Snus use in Sweden provides strong evidence in support of harm reduction.
• E-cigarettes are seen by many smokers as an attractive alternative to cigarettes.
• Regulated, safer nicotine alternatives may substantially improve public health.⁎ Correspondence to: K.O. Fagerström, Fagerström Con
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E-cigarettesOver the last 50 years, the concept of tobacco harm reduction has been well established. It is now understood that
nicotine itself is not very harmful and nicotine replacement therapy products have been widely used as an aid to
quit, reduce to quit or temporarily abstain from smoking formany years. The popularity of the unlicensed electronic
cigarette has increased despite an unknown risk proﬁle and snus use in Sweden provides strong evidence in support
of a harm reduction strategy. The regulatory environment around harm reduction has changed in the UK and is
continuing to evolve across the globe. The need formore appealing, licensed nicotine products capable of competing
with cigarettes sensorially, pharmacologically and behaviourally is considered by many to be the way forward. The
signiﬁcant positive impact on public health that could be gained from encouraging people to switch from cigarettes
to licensed medicinal nicotine products cannot be ignored.
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The concept of tobacco harm reduction is well established. In 1976,
Professor Michael Russell wrote: “People smoke for nicotine but they
die from the tar”, and suggested that the ratio of tar to nicotine could
be the key to safer smoking, speciﬁcally a low-tar, medium-nicotine
cigarette (Russell, 1976). Despite innovations in the mid-1970s, several
ﬁltered products delivered as much tar and nicotine as the original,
unﬁltered brands (Kozlowski & O'Connor, 2002). As understanding
improved, new research in 1982 conﬁrmed that smokers inhaled less
smoke from a nicotine-enriched cigarette than a control cigarette,
equal in all aspects besides nicotine yield (Fagerström, 1982).
Since the White Paper, ‘Smoking Kills’, was published in 1998
(Department of Health, 1998), a variety of tobacco-control policies to re-
duce smoke prevalence have been implemented in the UK, and around
the world (Royal College of Physicians, 2007). The National Institute for
Health andCare Excellence (NICE) deﬁned tobacco harm reduction as “re-
ducing the illnesses and deaths causedby smoking tobacco— among peo-
plewho smoke and those around them” (NICE, 2011). In parallel, medical
opinion has evolved, recognizing the potential health beneﬁt of smokers
shifting from cigarettes to pharmaceutically-regulated nicotine products.
In fact, in the last decade, the medical community has urged regulators
to consider harm reduction strategies to reduce rates of smoking (NICE,
2011; Royal College of Physicians, 2007, 2012). Similarly, in the USA, the
Family Smoking Prevention and Tobacco Control Act of 2009 aims to sig-
niﬁcantly reduce harm and the risk of tobacco-related disease to individ-
ual tobacco users (FDA, 2009).
Although medicinal nicotine products were initially regulated as
prescription only, they have been available over the counter (OTC) as
a General Sales List product for a decade in many countries. Further re-
strictions on the use of nicotine replacement therapy (NRT) in speciﬁc
populations, such as pregnant women, those with heart disease,
diabetes, liver or kidney problems, and children aged 12–18 years,
have gradually been minimized (MHRA, 2005), and the indication for
NRT extended to include ‘cut down to quit’ and ‘temporary abstinence’,
along with cessation (MHRA, 2010a). Most regulators, therefore, apply
no time limit for NRT use to support reduction, conﬁdent that this
alone facilitates quitting and may have direct health beneﬁts, not least12 week quit
Prescription only
1980s
12 week quit
Pharmacy only
1990s
GSL, General Sales List
1McNeil Products Limited. Nicorette® Inhalator SmPC. 2010
12 week quit
Cut down to stop and temporary abstinence 
GSL distribution
Children over 12 and pregnancy
2000s
Harm reduction indication
“Relieves and/or prevents craving and nicotine withdrawal symptoms ass
wishing to quit or reduce prior to quitting, to assist smokers who are unwi
smokers and those around them.” 1
2010s
Fig. 1. Nicotine replacement therapy regulto those living with the smoker. Similarly, many countries also support
‘temporary abstinence’ (Gartner, Hall, & McNeill, 2010). An overview of
approaches over time in the UK is presented in Fig. 1.
In 2009, the UK Medicines and Healthcare products Regulatory
Agency (MHRA) approved an extension to include harm reduction as
an indication for the Nicorette® Inhalator (McNeil AB, Helsingborg,
Sweden) (MHRA, 2009). Resulting from the review of its approach to
smoking cessation in 2010, it advocated an indication for harm reduc-
tion for all licensed nicotine-containing products (MHRA, 2010b).
The recently updated public health strategy in the UK recognizes
that many smokers may not want, or be able, to quit smoking, but
would like a safer alternative to cigarettes (HM Government, 2011).
NICE guidelines in the UK published in June 2013 recommendmedicinal
nicotine use on a long-term basis when needed to help people stop, cut
down prior to quitting, reduce their level of, or temporarily abstain
from, smoking. These guidelines cover the use of licensed nicotine-
containing products, and those that might be licensed by the MHRA in
the future such as those electronic cigarettes (e-cigarettes) demonstrat-
ing the necessary quality and safety standards (NICE, 2013).
In other countries, a harm reduction strategy is supported by an in-
creasing number of experts. While NRT is only licensed in this way in
the UK, the long-standing Swedish policy of accepting moist snuff
(snus) to compete with burnt tobacco has provided evidence of signiﬁ-
cant health beneﬁts; male smoking and tobacco-related mortality in
Sweden are among the lowest in the world (Rodu, Stegmayr, Nasic, &
Asplund, 2002). There is also evidence suggesting that snus uptake can re-
sult in moving from high- to low-risk tobacco use or quitting altogether
(Ramström, 2011). This indicates the beneﬁts that might conservatively
be expected if NRT was more widely licensed for harm reduction.
2. Safety of nicotine as an alternative to smoked tobacco
It is generally understood that it is not nicotine itself that is harmful,
but themethod of delivery, i.e. burning tobacco (ASH, 2007). Moreover,
it has been proposed that a switch of only 1% of smokers a year from
smoking to less harmful nicotine sources could potentially save around
60 000 lives in 10 years in the UK alone (Lewis, Arnott, Godfrey, &
Britton, 2005).ociated with tobacco dependence. It is indicated to aid smokers
lling or unable to quit and as a safer alternative to smoking for
ation in the UK over the last 30 years.
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Evenwith snus, which is not pharmaceutical-grade nicotine but a re-
ﬁned tobacco still containing nitrosamines and heavymetals, the causal
association with cancer is weak. Observations from long-term snus use
show little evidence, or inconsistent results, of increased cancer risk
compared with non-tobacco users (Lewin et al., 1998; Luo et al., 2007;
Schildt, Eriksson, Hardell, & Magnuson, 1998). Furthermore, a recent
meta-analysis found no association between snus and cancer of the oro-
pharynx, esophagus, stomach, pancreas, lung or other sites (Lee, 2011).
Formethodological and ethical reasons, little research has been done
on the long-term health effects (including cancer) of nicotine in
humans. However, the only large, long-term study published to date
(The Lung Health Study) found no link between NRT and cancer
among former smokers (Murray, Connett, & Zapawa, 2009).
This has lead both the UKMHRA and the Royal College of Physicians
to conclude that there is no evidence that medicinal nicotine causes
cancer (MHRA, 2010c; Royal College of Physicians, 2007). While many
components in tobacco smoke have been determined to be carcinogens,
authoritative bodies do not include nicotine in this list, including the
International Agency for Research on Cancer (International Agency for
Research on Cancer, 2007), the US Surgeon General (US Department
of Health & Human Services, 2010) and the US Food and Drug Adminis-
tration (FDA) (FDA, 2012).
2.2. Nicotine and cardiovascular disease
Although it is recognized that medicinal nicotine causes temporary
changes to the cardiovascular system during use (e.g. increased blood
pressure and elevated heart rate), these changes are transient
(Benowitz, Hansson, & Jacob, 2002). Furthermore, epidemiology studies
have not foundNRT use to be linked to the development of cardiovascu-
lar disease (CVD) (Greenland, Satterﬁeld, & Lanes, 1998; Hubbard et al.,
2005; Kimmel et al., 2001; Murray et al., 1996) and studies have shown
that NRT need not be contraindicated for smokers with CVD (Hubbard
et al., 2005; Joseph et al., 1996; McRobbie & Hajek, 2001). Several
studies have evaluated CVD risk in long-term users of snus; a recent
meta-analysis of eight prospective, observational studies concluded
that snus use was not associated with acute myocardial infarction
(Hansson et al., 2012).
The UK Royal College of Physicians states that NRT does not increase
the incidence of acute cardiovascular events or of sudden death in
healthy volunteers, the general population or in patients with
pre-existing CVD (Royal College of Physicians, 2007). Further the FDA
does not consider nicotine to be a signiﬁcant cardiovascular toxicant
(FDA, 2012).
3. Current alternative nicotine products
3.1. Nicotine replacement therapy
NRT is the term given to products containingmedicinal nicotine that
have met regulatory authority standards for quality, safety and efﬁcacy.Table 1
Nicotine replacement therapies available in the UK.
Information obtained from the British National Formulary.
Type Available doses
Nicotine transdermal patches Worn over 16 h: 5, 10, 15 and 25 mg
Worn over 24 h: 7, 14, 20, 21 and 30 mg
Nicotine chewing gum 2 and 4 mg
Nicotine sublingual tablet 2 mg
Nicotine lozenge 1, 1.5, 2 and 4 mg
Nicotine inhalation cartridge plus
mouthpiece
Cartridge containing 15 mg
Nicotine metered nasal spray 0.5 mg per spray
Nicotine oral spray 1 mg per sprayNRTs (patches, gums, lozenges, microtabs, sprays and inhalators) have
been studied extensively for over 30 years in helping smokers quit,
reduce to quit or temporarily abstain from smoking. Table 1 shows the
NRTs currently available in the UK.
NRT increases the rate of quitting by 50–70% when compared with
placebo or no treatment (Stead et al., 2012). However, on a population
level, the impact of NRT in absolute terms is modest. The proportion
of smokers considering making a quit attempt at any point is small,
and of those using NRT without any formal behavioral support, just
7–10% remain cigarette-free at 52 weeks (Stead, Perera, Bullen, Mant,
& Lancaster, 2008).
Although conventional NRTs do not adequately replicate the act of
cigarette smoking, the recent surge in the popularity of e-cigarettes
seems to be due in part to this very fact. Furthermore, there is growing
interest in the development of consumer-acceptable inhaled nicotine
delivery systems with absorption kinetics similar to typical cigarettes
as a harm reduction technique (Benowitz, 2008; Caldwell, Sumner, &
Crane, 2012).
3.2. E-cigarettes
Historically, e-cigarettes have been outside of the medicines licens-
ing regime, with no independent oversight of quality, safety or efﬁcacy.
However, as a result of the recent MHRA announcement to regulate all
nicotine-containing products as medicines, e-cigarettes will require a
medicine license in the UK from 2016. This should allow time for
manufacturers to ensure that their products meet the required medi-
cines' quality standard.
Several studies have reported e-cigarette use to aid smoking reduc-
tion or temporary abstinence (Caponnetto, Polosa, Russo, Leotta, &
Campagna, 2011; Polosa et al., 2011; Siegel, Tanwar, & Wood, 2011),
and as a quitting aid (Caponnetto et al., 2011; Siegel et al., 2011).
Another study has described their use to reduce nicotine craving, with
a signiﬁcant difference in craving levels reported with e-cigarettes
than placebo (Bullen et al., 2010).
There is, however, far less evidence regarding safety and quality of
e-cigarettes. Recent studies found that levels of nicotine (Goniewicz,
Kuma, Gawron, Knysak, & Kosmider, 2013) and nicotine-related impu-
rities (Trehy et al., 2011) varied considerably across brands. Nicotine
content was inaccurately labeled by some manufactures (Trehy et al.,
2011) and there is the possibility that metals, or chemicals from plastics
in the delivery device, may leach into the vapor before inhalation
(Williams, Villarreal, Bozhilov, Lin, & Talbot, 2013).
When smokers were asked to give their reasons for using
e-cigarettes, the most popular answers included a perception that
they are less harmful than tobacco, as a substitute for smoking where
smoking is not allowed, to quit or avoid relapse, to deal with tobacco
craving or tobacco-withdrawal symptoms and because they are cheaper
than smoking (ASH, 2012; Etter & Bullen, 2011).
4. Limitations of existing NRTs
Currently available forms of NRTmay fail to helpmany smokers quit
because they do not deliver nicotine in the same way as cigarettes
(Schneider, Lunell, Olmstead, & Fagerström, 1996; Schneider,
Olmstead, Franzon, & Lunell, 2001). However, smoking is a conditioned
habit that is triggered by various environmental cues, and smokers
enjoy the many rituals associated with smoking (Fagerström, 2012).
Most current NRTs do not replace these unique sensory cues or rituals
(Fagerström, 2012; Rose, 2006), making it difﬁcult to convince habitual
smokers to switch to them or to continue use once tried. After all,
cigarette smokers long for a cigarette, not nicotine, much like hunger
is directed to food, not carbohydrate.
The need for more appealing licensed nicotine products capable of
competing with cigarettes, and meeting smokers where they are rather
than beseeching them yet again to change, is considered by many to be
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than to use medicinal nicotine (MHRA, 2005) and a lifetime use of NRT
will be considerably less harmful than smoking (NICE, 2013). UK
smoking prevalence has plateaued in recent years to around 20%
(Ofﬁce for National Statistics, 2011), with a similar picture seen across
other western countries (European Commission, 2012). Smokers
know the risks, but ﬁnd quitting difﬁcult for a variety of reasons. New
medicinal nicotine products better replicating the smoking experience
have the potential to radically reduce both individual risk and public
smoking-related morbidity and mortality.5. Future challenges in harm reduction
The regulatory environment around harm reduction has changed in
the UK and continues to evolve across the globe. An important debate
persists, with reasonable concerns thatmust be considered. TheMHRA's
endorsement of harm reduction may seem logical given the alternative,
though there are risks that have to bemanaged, particularly as products
that look and feel more like a cigarette reach the market.
One example is the perception that medicinal nicotine could act as a
gateway to smoking tobacco, establishing a dependence on nicotine in
non-smokers, although several studies have challenged this. The data
analyzed indicate that those who start using smokeless tobacco are
less likely to smoke cigarettes (Rodu & Cole, 2010), and the odds of
initiating daily smoking are signiﬁcantly lower for men who start
using snus than for those who do not (Ramström & Foulds, 2006). Al-
though e-cigarettes may have a similar impact as snus, with regard to
the gateway hypothesis, further research is needed. A recent study in
theUK found that b1%of adultswhohad never smoked reported having
tried e-cigarettes (ASH, 2012). Similarly, an online study of 2649 adults
in the USA reported e-cigarette use in 0.8% of non-smokers (Pearson,
Richardson, Niaura, Vallone, & Abrams, 2012).
Nevertheless, the unintended consequences of advocating
e-cigarettes, particularly in adolescents, should be considered in future
research as their use increases. A recent survey among middle and
high-school students in the US showed that e-cigarette use had doubled
in the space of a year; ever e-cigarette use increased from 3.3% to 6.8%;
current e-cigarette use increased from 1.1% to 2.1%; and current use of
both conventional and e-cigarettes increased from 0.8% to 1.6% from
2011 to 2012 (Corey et al., 2013). However, it appears that current
e-cigarette use in children is largely conﬁned to those who have already
tried smoking. One recent survey commissioned by Action on Smoking
and Health in the UK report that among 16–18-year-olds who have
never smoked, only 1% have tried e-cigarettes once or twice (ASH,
2013).
It is possible that adolescents with co-morbidities or behavioral
problems seeking relief from their symptoms by use of nicotine may
be more likely to turn to e-cigarettes as they become widespread.
This, of itself, may not be a bad thing, provided that e-cigarettes are
being used as an alternative by adolescents who would otherwise
have smoked, and that it does not lead to ‘gateway’ among those who
would not.
Until now there was the concern that unregulated e-cigarettes
claiming health beneﬁt over cigarettes could cause negative effects
currently not seen with cigarettes. Medicinal nicotine, licensed as NRT,
undergoes careful quantitative and qualitative analysis of its composi-
tion at key points throughout its shelf-life. This enables manufacturers,
regulators and consumers to be conﬁdent of its quality and safety. Al-
though e-cigarettes are currently not subjected to the same testing
and regulatory authority data review, the requirement for a medicines
license from 2016 should negate these concerns in the future. Until
that time, while likely to be safer than cigarettes, evidence of safety
relating to medicinal nicotine, gained over N30 years' marketed experi-
ence and laboratory testing, cannot be extrapolated to apply to them in
equal measure.It was envisaged, based on the draft European Tobacco Product
Directive, that a similar policy towards the licensing of e-cigarettes
would be adopted across the EU, although this is unlikely now. While
this could provide the assurances that consumers should expect regard-
ing safety and quality, and support the advertising of these products in a
responsible way, there are some concerns that need to be addressed.
Unfortunately, the level of market access for medicinal OTC products
varies by country, even in the EU. In the UK, NRT available on the
General Sales List can compete effectively with tobacco at the point of
sale without pharmacist or other healthcare professional oversight. In
many other EU countries, these products must be sold in pharmacies,
often only displayed ‘behind the counter’. Individual EU Governments
can remedy this within the existing medicines legislation, and
must do so for medicines regulation to offer a compelling regulatory
framework for e-cigarettes across the region.
There seems to be some agreement, however, that the popularity of
e-cigarettes is because they more closely address the smokers' needs
than currently available NRTs. Therefore, licensed, medicinal nicotine-
containing products are required that can demonstrate a safety proﬁle
similar to other NRT products, but that also satisfy smokers' needs for
rapid nicotine delivery and the smoking ritual.
Following the harm reduction indication for NRT in the UK, the to-
bacco industry has started to invest in products that canmeetmedicines
legislation quality standards (British American Tobacco, 2011). These
corporations are committed to meeting the needs of smokers, which
of course includes ﬁnding safer but equally satisfying alternatives to cig-
arettes. They will not want their products to be over-medicalized as
smokers do not see themselves as ill, and so do not seek a medicine.
However, some companies are demonstrating that they are prepared
toworkwithin a regulatory framework focusing onmedicines' standard
quality and safety, allowing appropriate oversight of communication
through advertising to smokers. If the model proposed by the MHRA
receives wider acceptance, we believe that the tobacco industry could
actually become part of the solution to cigarette smoking, investing
their resources in a more targeted way towards ﬁnding satisfying
alternatives for those who do not wish, or are unable, to eliminate
nicotine from their lives.
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